Osimertinib early dose reduction as a risk to brain metastasis control in EGFR‐mutant non‐small cell lung cancer

BACKGROUND: The epidermal growth factor receptor (EGFR) mutation is a risk factor associated with brain metastases (BMs) in patients with non‐small cell lung cancer (NSCLC). This study aimed to evaluate the impact of osimertinib early dose reduction on BM worsening. METHODS: We retrospectively analy...

Descripción completa

Detalles Bibliográficos
Autores principales: Tozuka, Takehiro, Noro, Rintaro, Miyanaga, Akihiko, Nakamichi, Shinji, Takeuchi, Susumu, Matsumoto, Masaru, Kubota, Kaoru, Kasahara, Kazuo, Seike, Masahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10524078/
https://www.ncbi.nlm.nih.gov/pubmed/37691552
http://dx.doi.org/10.1002/cam4.6393

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10524078/
https://www.ncbi.nlm.nih.gov/pubmed/37691552
http://dx.doi.org/10.1002/cam4.6393

Ejemplares similares